Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease

Por Fleseriu, Maria, Pivonello, Rosario, Young, Jacques, Hamrahian, Amir H., Molitch, Mark E., Shimizu, Chikara, Tanaka, Tomoaki, Shimatsu, Akira, White, Tracy, Hilliard, Annie, Tian, Chuan, Sauter, Nicholas, Biller, Beverly MK, Bertagna, Xavier
Publicado no Pituitary (2015)